Match tier Likely match
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-06

Joshua Xu

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Role not yet determined Is this you? Add your title

Also affiliated: The University of Sydney (2016); United States Food and Drug Administration (2008–2026); University Health Network (2022–2026); University of Calgary (2026); Duke University (2014); Fudan University (2022); Royal North Shore Hospital (2016); Government of the United States of America (2021); Princess Margaret Cancer Centre (2022–2026); Regenxbio (United States) (2024); University of Michigan–Flint (2016); State Key Laboratory of Genetic Engineering (2022); ICF International (United States) (2010–2012); McMaster University (2021–2022)

30 h-index 197 pubs 4,878 cited

  • Humans
  • High-Throughput Nucleotide Sequencing
  • Gene Expression Profiling
  • Animals
  • Artificial Intelligence
  • Drug Labeling
  • United States Food and Drug Administration
  • Sequence Analysis, RNA
  • Precision Medicine
  • United States
  • Neoplasms
  • Oligonucleotide Array Sequence Analysis
  • Polymorphism, Single Nucleotide
  • Quality Control
  • Algorithms

Biography and Research Information

OverviewAI-generated summary

Joshua Xu's research program investigates the application of high-throughput sequencing technologies and computational methods for gene expression analysis and predictive modeling. His work has focused on evaluating and comparing different platforms, such as microarrays and RNA sequencing, for their utility in clinical endpoint prediction and biomarker discovery.

Xu has been involved in collaborative studies, including the MicroArray Quality Control (MAQC)-II project, which aimed to establish best practices for developing and validating microarray-based predictive models. His research also extends to assessing the analytical validity of sequencing assays for precision oncology and exploring the integration of multi-omics data. He has co-authored numerous publications with key collaborators, including Leihong Wu, Weida Tong, and Binsheng Gong, primarily from the National Center for Toxicological Research, and Donald J. Johann from the University of Arkansas for Medical Sciences.

With a scholarly output reflected in 198 publications and an h-index of 30, Xu is recognized as a highly cited researcher. His work leverages artificial intelligence and machine learning techniques for applications such as species identification in food contaminants, demonstrating a broad interest in computational approaches to biological and toxicological research.

Metrics

  • h-index: 30
  • Publications: 197
  • Citations: 4,878

Selected Publications

  • Ensuring multiomics data reproducibility for artificial intelligence with reference materials as a common calibrator (2026)
    Nature Biotechnology 1 citation DOI OpenAlex
  • Does generative AI mean the “end of history” for pharmacovigilance automation? towards a framework for the future of human-AI systems (2026)
    Frontiers in Drug Safety and Regulation DOI OpenAlex
  • Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations (2025)
    npj Precision Oncology 5 citations DOI OpenAlex
  • Federated learning: a privacy-preserving approach to data-centric regulatory cooperation (2025)
    Frontiers in Drug Safety and Regulation 12 citations DOI OpenAlex
  • Zika and dengue viruses differentially modulate host mRNA processing factors defining its virulence (2025)
    NAR Molecular Medicine 1 citation DOI OpenAlex
  • Biomarkers of Neurotoxicity and Disease (2025)
    Elsevier eBooks 1 citation DOI OpenAlex
  • Leveraging FDA Labeling Documents and Large Language Model to Enhance Annotation, Profiling, and Classification of Drug Adverse Events with AskFDALabel (2025)
    Drug Safety 16 citations DOI OpenAlex
  • Developing a Charlson Comorbidity Index for the American Indian Population Using the Epidemiologic Data from the Strong Heart Study (2024)
    Journal of Racial and Ethnic Health Disparities 1 citation DOI OpenAlex
  • Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1 (2024)
    Experimental Biology and Medicine 4 citations DOI OpenAlex
  • Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing (2024)
    Scientific Data 11 citations DOI OpenAlex
  • Description and Validation of a Novel AI Tool, LabelComp, for the Identification of Adverse Event Changes in FDA Labeling (2024)
    Drug Safety 9 citations DOI OpenAlex
  • Assessing the performance of large language models in literature screening for pharmacovigilance: a comparative study (2024)
    Frontiers in Drug Safety and Regulation 16 citations DOI OpenAlex
  • Automatic text classification of drug-induced liver injury using document-term matrix and XGBoost (2024)
    Frontiers in Artificial Intelligence 7 citations DOI OpenAlex
  • PERform: assessing model performance with predictivity and explainability readiness formula (2024)
    Journal of Environmental Science and Health Part C 2 citations DOI OpenAlex
  • Towards accurate indel calling for oncopanel sequencing through an international pipeline competition at precisionFDA (2024)
    Scientific Reports 3 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

501 Collaborators 174 Institutions 21 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics